Evidence map›Paper›PMID 34984325›Full record

ArticleiScience2022

Sequence and functional characterization of a public HIV-specific antibody clonotype.

Amyn A Murji, Nagarajan Raju, Juliana S Qin, Haajira Kaldine, Katarzyna Janowska, Emilee Friedman Fechter, Rutendo Mapengo, Cathrine Scheepers, Ian Setliff, Priyamvada Acharya and 2 more

Open access · goldAbstract read
In one paragraph

Article in iScience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
  3. Landscape of infection enhancing antibodies in COVID-19 and healthy donors.Computational and structural biotechnology journal · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Amyn A MurjiDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
Nagarajan RajuDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
Juliana S QinVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Haajira KaldineNational Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg 2131, South Africa.
Katarzyna JanowskaDivision of Structural Biology, Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Emilee Friedman FechterVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Rutendo MapengoNational Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg 2131, South Africa.
Cathrine ScheepersNational Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg 2131, South Africa.
Ian SetliffVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Priyamvada AcharyaDivision of Structural Biology, Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Lynn MorrisNational Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg 2131, South Africa.
Ivelin S GeorgievDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
Vanderbilt University Medical Center · USNational Health Laboratory Service · ZADuke University · USVanderbilt University · US

Funding

Tennessee CFAR: Implementation of Culturally Responsive Trauma-Informed Care with Youth with HIV in Memphis, TNP30AI110527 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Stephany Norah Duda · 2015 to 2026
$27.5M
The Viral Set Point in HIV-1 Subtype C InfectionU19AI051794 · NIAID · UNIVERSITY OF KWAZULU-NATAL · PI ABDOOL KARIM, SALIM S · 2002 to 2007
$22.5M
Targeting early metastable intermediates of the SARS-CoV-2 spike for vaccine and therapeutics developmentR01AI145687 · NIAID · DUKE UNIVERSITY · PI Priyamvada Acharya · 2019 to 2026
$6.9M
Neutralization Fingerprinting Analysis of Polyclonal Antibody Responses against HIV-1R01AI131722 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI GEORGIEV, IVELIN · 2017 to 2021
$4.5M
Chemical Biology of Infectious Diseases (CBID) Training ProgramT32AI112541 · NIAID · VANDERBILT UNIVERSITY · PI Eric P Skaar · 2015 to 2026
$4.0M
Immunoglobulin gene diversity in an African population and impact on antibody function in HIV infectionU01AI136677 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI MORRIS, LYNN · 2017 to 2021
$1.2M
NIAID NIH HHS P30 AI110527NIAID NIH HHS R01 AI131722NIAID NIH HHS R01 AI145687NIAID NIH HHS T32 AI112541NIAID NIH HHS U01 AI136677NIAID NIH HHS U19 AI051794
6 · The paper itself

Abstract

Public antibody clonotypes shared among multiple individuals have been identified for several pathogens. However, little is known about the determinants of antibody "publicness". Here, we characterize the sequence and functional properties of antibodies from a public clonotype targeting the CD4 binding site on HIV-1 Env. Our results showed that HIV-1 specificity for the public antibodies studied here, comprising sequences from three individuals, was modulated by the V

Indexed as

ImmunologyVirology

Identifiers

PMID34984325
PMCPMC8692997
OpenAlexW3216247522

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.